Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Aytu BioScience stock

AYTU
US0547548745
A2QJRT

Price

1.65
Today +/-
+0.06
Today %
+3.70 %

Aytu BioScience stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Aytu BioScience stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Aytu BioScience stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Aytu BioScience stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Aytu BioScience's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Aytu BioScience Stock Price History

DateAytu BioScience Price
12/6/20241.65 undefined
12/5/20241.59 undefined
12/4/20241.57 undefined
12/3/20241.59 undefined
12/2/20241.63 undefined
11/29/20241.61 undefined
11/27/20241.61 undefined
11/26/20241.60 undefined
11/25/20241.57 undefined
11/22/20241.63 undefined
11/21/20241.51 undefined
11/20/20241.49 undefined
11/19/20241.60 undefined
11/18/20241.60 undefined
11/15/20241.55 undefined
11/14/20241.55 undefined
11/13/20241.86 undefined
11/12/20241.74 undefined
11/11/20241.77 undefined
11/8/20241.64 undefined

Aytu BioScience Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Aytu BioScience, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Aytu BioScience from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Aytu BioScience’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Aytu BioScience. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Aytu BioScience’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Aytu BioScience’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Aytu BioScience’s growth potential.

Aytu BioScience Revenue, EBIT and net profit per share

DateAytu BioScience RevenueAytu BioScience EBITAytu BioScience Net Income
2030e141.07 M undefined0 undefined0 undefined
2029e131.89 M undefined1.12 M undefined0 undefined
2028e123.73 M undefined-1.73 M undefined0 undefined
2027e120.05 M undefined10.72 M undefined-2.06 M undefined
2026e71 M undefined5.46 M undefined3.45 M undefined
2025e71.75 M undefined3.23 M undefined1.44 M undefined
202481 M undefined-2.89 M undefined-15.84 M undefined
2023107.4 M undefined-11.4 M undefined-17.1 M undefined
202296.7 M undefined-34.4 M undefined-108.8 M undefined
202165.6 M undefined-38.2 M undefined-58.3 M undefined
202027.6 M undefined-20.9 M undefined-13.6 M undefined
20197.3 M undefined-16.9 M undefined-27.1 M undefined
20183.7 M undefined-17.8 M undefined-10.2 M undefined
20173.2 M undefined-18.8 M undefined-22.5 M undefined
20162.6 M undefined-14.2 M undefined-28.2 M undefined
2015300,000 undefined-7.6 M undefined-7.7 M undefined
20140 undefined-100,000 undefined-100,000 undefined
20130 undefined-100,000 undefined-100,000 undefined
20120 undefined-100,000 undefined-100,000 undefined
20110 undefined-100,000 undefined-100,000 undefined
20100 undefined-100,000 undefined-100,000 undefined
20090 undefined-100,000 undefined-100,000 undefined
20080 undefined-100,000 undefined-100,000 undefined
20070 undefined0 undefined0 undefined

Aytu BioScience Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
0000000002337276596107817170120123131141
----------50.00-133.33285.71140.7447.6911.46-24.30-12.35-1.4171.432.506.507.63
---------50.0033.3333.3371.4374.0744.6254.1761.6866.6776.0677.1445.0043.9041.2238.30
00000000011152029526654000000
00000000-7-28-22-10-27-13-58-108-17-1513-2000
---------300.00-21.43-54.55170.00-51.85346.1586.21-84.26-11.76-106.67200.00-166.67---
00000000000000.20.81.53.35.54000000
------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Aytu BioScience Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Aytu BioScience is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
200720082009201020112012201320142015201620172018201920202021202220232024
                                   
000000007.49.10.871148.149.619.42320.01
000000000.20.20.50.61.75.628.221.728.923.62
000000000000000000
0000000000.51.31.31.41016.310.81212.63
000000000.50.30.40.51.311.711.188.95.64
000000008.110.139.415.475.4105.259.972.861.89
0000000000.20.60.20.20.98.76.33.91.52
000000000000000000
000000000000000000
000000009.713.611.111.419.148.985.570.65952.45
000000000.10.20.20028.165.8000
000000000.30.200000.50.80.82.23
0000000010.114.211.911.619.377.9160.577.763.756.2
0000000018.224.314.92134.7153.3265.7137.6136.5118.1
                                   
100200200200400400400500-5,000000000001
000000003956.673.192.7113.5215315.9334.6343.5347.69
-0.1-0.2-0.3-0.3-0.5-0.5-0.6-0.6-18.4-46.6-69.1-79.3-106.4-120-178.3-288.5-304.1-319.97
000000000000000000
000000000000000000
00-0.1-0.1-0.1-0.1-0.2-0.115.610413.47.195137.646.139.427.72
000000001.23.52.22.12.312.82820.524.520.4
000000000.21.21.10.7211.149.535.93729.32
000000000.15.40.30.51.14.97.44.15.88.25
000.10.10.10.10.100000007.93.81.62.4
0000000000000016.70.10.11.86
000.10.10.10.10.101.510.13.63.35.428.8109.564.46962.23
000000000000000.214.314.710.88
000000000000000000
000000001.14.27.44.222.329.518.512.813.417.27
000000001.14.27.44.222.329.518.727.128.128.15
000.10.10.10.10.102.614.3117.527.758.3128.291.597.190.38
000000-0.1-0.118.224.31520.934.8153.3265.8137.6136.5118.09
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Aytu BioScience provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Aytu BioScience's financial health and stability.

Assets

Aytu BioScience's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Aytu BioScience must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Aytu BioScience after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Aytu BioScience's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20072008200920102011201220132014201520162017201820192020202120222023
00000000-7-28-22-10-27-13-58-110-17
000000000042269108
00000000000000000
0000000002-100-121-10-5
000000001145-710-821818
00000000000001133
00000000000000000
00000000-6-10-13-15-13-28-25-28-5
000000000-10000-200
00000000-1-5-30-1-5-2-30
00000000-1-4-30-1-50-30
00000000000000000
0000000075005-16-3-5-2
0000000051111251592451115
000000001216102219713018
-----------1.00-2.00-1.00-5.00-11.00-4.00-4.00
00000000000000000
0000000040-764371-303
-0.03-0.05-0.05-0.05-0.06-0.04-0.04-0.04-6.63-11.95-13.94-16.01-13.89-28.37-28.3-28.82-5.13
00000000000000000

Aytu BioScience stock margins

The Aytu BioScience margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Aytu BioScience. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Aytu BioScience.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Aytu BioScience's sales revenue. A higher gross margin percentage indicates that the Aytu BioScience retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Aytu BioScience's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Aytu BioScience's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Aytu BioScience's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Aytu BioScience. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Aytu BioScience's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Aytu BioScience Margin History

Aytu BioScience Gross marginAytu BioScience Profit marginAytu BioScience EBIT marginAytu BioScience Profit margin
2030e67.39 %0 %0 %
2029e67.39 %0.85 %0 %
2028e67.39 %-1.4 %0 %
2027e67.39 %8.93 %-1.71 %
2026e67.39 %7.69 %4.86 %
2025e67.39 %4.5 %2.01 %
202467.39 %-3.57 %-19.56 %
202362.01 %-10.61 %-15.92 %
202254.08 %-35.57 %-112.51 %
202144.51 %-58.23 %-88.87 %
202072.83 %-75.72 %-49.28 %
201969.86 %-231.51 %-371.23 %
201843.24 %-481.08 %-275.68 %
201756.25 %-587.5 %-703.13 %
201661.54 %-546.15 %-1,084.62 %
201566.67 %-2,533.33 %-2,566.67 %
201467.39 %0 %0 %
201367.39 %0 %0 %
201267.39 %0 %0 %
201167.39 %0 %0 %
201067.39 %0 %0 %
200967.39 %0 %0 %
200867.39 %0 %0 %
200767.39 %0 %0 %

Aytu BioScience Stock Sales Revenue, EBIT, Earnings per Share

The Aytu BioScience earnings per share therefore indicates how much revenue Aytu BioScience has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Aytu BioScience earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Aytu BioScience's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Aytu BioScience’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Aytu BioScience's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Aytu BioScience Revenue, EBIT and net profit per share

DateAytu BioScience Sales per ShareAytu BioScience EBIT per shareAytu BioScience Earnings per Share
2030e22.94 undefined0 undefined0 undefined
2029e21.45 undefined0 undefined0 undefined
2028e20.12 undefined0 undefined0 undefined
2027e19.52 undefined0 undefined-0.33 undefined
2026e11.54 undefined0 undefined0.56 undefined
2025e11.67 undefined0 undefined0.23 undefined
202414.63 undefined-0.52 undefined-2.86 undefined
202332.55 undefined-3.45 undefined-5.18 undefined
202264.47 undefined-22.93 undefined-72.53 undefined
202182 undefined-47.75 undefined-72.88 undefined
2020138 undefined-104.5 undefined-68 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined
20110 undefined0 undefined0 undefined
20100 undefined0 undefined0 undefined
20090 undefined0 undefined0 undefined
20080 undefined0 undefined0 undefined
20070 undefined0 undefined0 undefined

Aytu BioScience business model

Aytu BioScience Inc. is a pharmaceutical company based in Englewood, Colorado. The company was founded in 2015 by Joshua Disbrow, who previously worked at Arbor Pharmaceuticals and Avadel Pharmaceuticals. Aytu specializes in the development of medications and medical products focused on respiratory diseases, infectious diseases, and urology. One of their main products is Natesto, a gel used to administer testosterone to men with low testosterone levels. They also have Tuzistra XR, an extended-release cough medicine, and a partnership with Kitov Pharma for the distribution of Consensi, a combination medication for high blood pressure and osteoarthritis. Another important product is MiOXSYS, a non-invasive diagnostic test for assessing male fertility. Aytu also has a business model focused on acquiring established products, such as ZolpiMist for sleep disorders, FemiNAT for cervical cancer testing, and Healight for HIV testing. They collaborate with other companies to develop new technologies and acquire products, such as Urology Health Solutions with Innovus Pharmaceuticals and INTERCEPT Blood Platelets and Plasma with Cerus Corporation. Overall, Aytu BioScience Inc. is an innovative company focused on the development and acquisition of products in the areas of respiratory diseases, infectious diseases, and urology, with the potential to improve many people's lives and revolutionize the pharmaceutical industry. Aytu BioScience is one of the most popular companies on Eulerpool.com.

Aytu BioScience SWOT Analysis

Strengths

Aytu BioScience Inc is a research-driven biopharmaceutical company specializing in the development and commercialization of novel products in the field of urology and sexual wellness. The company has a strong portfolio of innovative therapies targeting various unmet needs in these areas.

Aytu BioScience Inc has a dedicated team of experienced scientists, researchers, and professionals who are focused on driving advancements in medical treatments and improving patient outcomes. Their expertise and commitment contribute to the overall strength of the company.

Weaknesses

One of the weaknesses of Aytu BioScience Inc is its relatively small market presence compared to larger pharmaceutical companies. The limited market share may pose challenges in terms of market penetration and competition.

Additionally, as a research-driven company, Aytu BioScience Inc heavily relies on successful product development and regulatory approvals. Delays or failures in these areas may impact the company's growth and profitability.

Opportunities

Aytu BioScience Inc operates in a sector with significant growth potential. The increasing prevalence of urological and sexual wellness disorders and the growing demand for effective treatments provide opportunities for the company to expand its market reach and increase its revenue.

In addition, the advancements in medical technology and the emergence of personalized medicine open doors for Aytu BioScience Inc to develop targeted therapies that can provide better outcomes and enhance patient care.

Threats

Aytu BioScience Inc faces threats from intense competition in the biopharmaceutical industry. Larger pharmaceutical companies with greater resources and marketing capabilities may pose challenges in terms of market share acquisition and brand recognition.

Moreover, regulatory uncertainties, changes in healthcare policies, and the potential for legal and intellectual property disputes can also impact the company's operations and financial performance.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Aytu BioScience Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Aytu BioScience historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Aytu BioScience shares outstanding

The number of shares was Aytu BioScience in 2023 — This indicates how many shares 3.3 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Aytu BioScience earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Aytu BioScience's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Aytu BioScience’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Aytu BioScience's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Aytu BioScience stock splits

In Aytu BioScience's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Aytu BioScience.

Aytu BioScience latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.35 0.44  (226.87 %)2025 Q1
6/30/2024-0.46 -0.82  (-78.65 %)2024 Q4
3/31/2024-0.65 -0.52  (20.34 %)2024 Q3
12/31/2023-0.26 -0.04  (84.31 %)2024 Q2
9/30/2023-0.04 -1.48  (-3,527.45 %)2024 Q1
6/30/2023-0.97 -0.59  (39.11 %)2023 Q4
3/31/2023-0.64 -1.93  (-200.34 %)2023 Q3
12/31/2022-1.63 -1.31  (19.73 %)2023 Q2
9/30/2022-3.67 -1.2  (67.32 %)2023 Q1
6/30/2022-7.55 -9.8  (-29.84 %)2022 Q4
1
2
3
4

Eulerpool ESG Scorecard© for the Aytu BioScience stock

Eulerpool World ESG Rating (EESG©)

18/ 100

🌱 Environment

20

👫 Social

22

🏛️ Governance

13

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Aytu BioScience shareholders

%
Name
Stocks
Change
Date
17.67174 % Nantahala Capital Management, LLC1,086,81206/30/2024
7.68242 % Stonepine Capital Management, LLC472,46906/30/2024
4.09756 % Armistice Capital LLC252,000252,0006/30/2024
1.20525 % Renaissance Technologies LLC74,1232,8006/30/2024
1.16408 % Disbrow (Joshua R.)71,59108/31/2024
0.58405 % Geode Capital Management, L.L.C.35,9191,3566/30/2024
0.45346 % The Vanguard Group, Inc.27,88806/30/2024
0.38294 % Dimensional Fund Advisors, L.P.23,5518,3116/30/2024
0.37699 % Pyszczymuka (Greg)23,1852099/30/2024
0.37062 % BlackRock Institutional Trust Company, N.A.22,79306/30/2024
1
2
3
4
5
...
7

Aytu BioScience Executives and Management Board

Mr. Joshua Disbrow

(48)
Aytu BioScience Chairman of the Board, Chief Executive Officer (since 2015)
Compensation 708,000

Mr. Greg Pyszczymuka

(44)
Aytu BioScience Chief Commercial Officer
Compensation 540,046

Mr. Mark Oki

(54)
Aytu BioScience Chief Financial Officer, Treasurer, Company Secretary
Compensation 522,840

Mr. John Donofrio

(55)
Aytu BioScience Independent Director
Compensation 90,000

Ms. Vivian Liu

(59)
Aytu BioScience Independent Director
Compensation 89,620
1
2

Aytu BioScience Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Reckitt Benckiser Group Stock
Reckitt Benckiser Group
SupplierCustomer0,41-0,67-0,290,230,150,83
Merck Stock
Merck
SupplierCustomer0,380,700,580,78-0,19-0,87
1

Most common questions regarding Aytu BioScience

What values and corporate philosophy does Aytu BioScience represent?

Aytu BioScience Inc represents values of innovation, commitment to patient healthcare, and enhancing medical outcomes. The company's corporate philosophy revolves around providing unique therapeutic solutions to unmet medical needs. Aytu BioScience Inc actively seeks out strategic partnerships, allowing them to expand their product portfolio and maximize global commercial potential. With a focus on delivering innovative treatments, Aytu BioScience Inc aims to improve patient quality of life and promote better healthcare outcomes. Their dedication to research and development ensures the continuous advancement of medical solutions, enabling them to positively impact the lives of patients worldwide.

In which countries and regions is Aytu BioScience primarily present?

Aytu BioScience Inc is primarily present in the United States.

What significant milestones has the company Aytu BioScience achieved?

Aytu BioScience Inc has achieved several significant milestones. The company successfully completed the merger with Innovus Pharmaceuticals, expanding its product portfolio and enhancing its market presence. Aytu BioScience obtained FDA clearance for its rapid COVID-19 IgG/IgM antibody test, making it one of the first companies to receive such clearance during the pandemic. Moreover, the company secured the US commercial rights for a novel male infertility product, Natesto, further diversifying its therapeutic offerings. Aytu BioScience also established partnerships with reputable organizations, including Apollo Med Innovations and an exclusive licensing agreement with Aytu's COVID-19 IgG/IgM antibody test manufacturer, Zhejiang Orient Gene Biotech. These milestones demonstrate Aytu BioScience's commitment to innovation and growth.

What is the history and background of the company Aytu BioScience?

Aytu BioScience Inc is a leading pharmaceutical company specializing in acquiring, developing, and commercializing innovative products for urological and related conditions. Founded in 2015, Aytu BioScience focuses on developing and marketing products that meet the needs of both healthcare professionals and patients. Their diverse product portfolio includes treatments for conditions such as male infertility, low testosterone, and prostate cancer. Aytu BioScience is committed to improving patients' lives through their dedication to scientific innovation and advanced healthcare solutions. With a strong focus on urology, the company continues to make significant contributions to the field of healthcare.

Who are the main competitors of Aytu BioScience in the market?

The main competitors of Aytu BioScience Inc in the market include companies such as Johnson & Johnson, Pfizer Inc, and Merck & Co. These pharmaceutical giants are well-established players in the healthcare industry, offering a wide range of products and services that often overlap with Aytu BioScience's focus areas. While Aytu BioScience Inc may face fierce competition from these industry leaders, the company's unique product offerings and innovative approaches set it apart in the market.

In which industries is Aytu BioScience primarily active?

Aytu BioScience Inc is primarily active in the pharmaceutical and biotechnology industries. With a focus on developing and commercializing innovative products, Aytu BioScience Inc works towards addressing unmet medical needs in various therapeutic areas. The company specializes in areas such as urology, infectious diseases, and dermatology. By leveraging their expertise and collaborations, Aytu BioScience Inc aims to improve patient outcomes and deliver novel healthcare solutions.

What is the business model of Aytu BioScience?

The business model of Aytu BioScience Inc is focused on acquiring, developing, and commercializing novel products in the healthcare sector. Aytu BioScience primarily focuses on urology and related conditions to improve patient care and outcomes. The company seeks to identify potential therapies, acquire the rights to develop and commercialize them, and bring them to market. By leveraging strategic partnerships and collaborations, Aytu BioScience aims to address unmet medical needs and deliver innovative solutions to patients. Through its comprehensive approach, Aytu BioScience strives to optimize healthcare and make a positive impact in the field of urology and beyond.

What is the P/E ratio of Aytu BioScience 2024?

The Aytu BioScience P/E ratio is -0.58.

What is the P/S ratio of Aytu BioScience 2024?

The Aytu BioScience P/S ratio is 0.11.

What is the Quality Investing of Aytu BioScience?

The Quality Investing for Aytu BioScience is 4/10.

What is the revenue of Aytu BioScience 2024?

The Aytu BioScience revenue is 81 M USD.

How high is the profit of Aytu BioScience 2024?

The Aytu BioScience profit is -15.84 M USD.

What is the business model of Aytu BioScience

Aytu BioScience Inc is a biopharmaceutical company based in Englewood, Colorado. The company specializes in the development and commercialization of innovative medical products aimed at improving the quality of life for patients. Aytu BioScience has focused on the areas of urology, neurology, and hematology and has a broad portfolio of products that meet the needs of patients in these areas.

What is the Aytu BioScience dividend?

Aytu BioScience pays a dividend of 0 USD distributed over payouts per year.

How often does Aytu BioScience pay dividends?

The dividend cannot currently be calculated for Aytu BioScience or the company does not pay out a dividend.

What is the Aytu BioScience ISIN?

The ISIN of Aytu BioScience is US0547548745.

What is the Aytu BioScience WKN?

The WKN of Aytu BioScience is A2QJRT.

What is the Aytu BioScience ticker?

The ticker of Aytu BioScience is AYTU.

How much dividend does Aytu BioScience pay?

Over the past 12 months, Aytu BioScience paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aytu BioScience is expected to pay a dividend of 0 USD.

What is the dividend yield of Aytu BioScience?

The current dividend yield of Aytu BioScience is .

When does Aytu BioScience pay dividends?

Aytu BioScience pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aytu BioScience?

Aytu BioScience paid dividends every year for the past 0 years.

What is the dividend of Aytu BioScience?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aytu BioScience located?

Aytu BioScience is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aytu BioScience kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aytu BioScience from 12/7/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/7/2024.

When did Aytu BioScience pay the last dividend?

The last dividend was paid out on 12/7/2024.

What was the dividend of Aytu BioScience in the year 2023?

In the year 2023, Aytu BioScience distributed 0 USD as dividends.

In which currency does Aytu BioScience pay out the dividend?

The dividends of Aytu BioScience are distributed in USD.

All fundamentals about Aytu BioScience

Our stock analysis for Aytu BioScience Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aytu BioScience Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.